Skip to main content

Table 2 Best response to nivolumab (RECIST v 1.1) based on RCC histology

From: Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

Histology N PR SD PD Non-evaluable
Papillary 16 2 (14%) 3 (21%) 9 (64%) 2
Unclassified 14 4 (36%) 3 (27%) 4 (36%) 3
Chromophobe 5 0 (0%) 3 (75%) 1 (25%) 1
Collecting Duct 4 1 (25%) 0 (0%) 3 (75%) 0
MTSCC 1 0 (0%) 1 (100%) 0 (0%) 0
Translocation 1 0 (0%) 0 (0%) 1 (100%) 0
All Histologies 41 7 (20%) 10 (29%) 18 (51%) 6
  1. No complete responses (CRs) were observed in this study
  2. For some histologies total percentages do not add up to 100% due to rounding
  3. Abbreviations: RECIST Response Criteria in Solid Tumors, PR Partial Response, SD Stable Disease, PD Progressive Disease, MTSCC Mucinous Tubular and Spindle Cell Carcinoma